August 8, 2024 – Ethicon, a Johnson & Johnson MedTech firm, introduced that the U.S. Meals & Drug Administration (FDA) has accredited a label replace to increase the supply of the LINX™ Reflux Administration System to sufferers with Barrett’s esophagus (BE) who expertise gastroesophageal reflux illness (GERD) signs. The choice is predicated on a retrospective assessment of a 2021 examine that discovered LINX™ to be protected and efficient in treating GERD signs in sufferers with BE.

It’s estimated that 20 % of adults within the U.S. have GERD, which is a danger issue for BE, a situation during which tissue just like the liner of the intestines replaces the liner of the esophagus.^2,3 Thousands and thousands of sufferers depend on drugs that regulate or suppress acid manufacturing within the abdomen to deal with GERD. Nonetheless, these drugs don’t tackle the mechanical reason for GERD, particularly a weak decrease esophageal sphincter (LES) muscle. LINX™, a versatile ring of small magnets positioned across the LES to assist stop acid reflux disease, has been proven to achieve success in treating GERD in sufferers with and with out BE.

Extra data